Provided by Tiger Trade Technology Pte. Ltd.

Cognition Therapeutics, Inc

0.8912
-0.0688-7.17%
Volume:791.86K
Turnover:742.32K
Market Cap:84.75M
PE:-4.60
High:0.9876
Open:0.9800
Low:0.8900
Close:0.9600
52wk High:2.05
52wk Low:0.5501
Shares:95.09M
Float Shares:85.42M
Volume Ratio:2.06
T/O Rate:0.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1936
EPS(LYR):-0.3228
ROE:-83.76%
ROA:-78.18%
PB:2.57
PE(LYR):-2.76

Loading ...

Cognition Therapeutics - Registrational Program for Zervimesine in Dlb Psychosis to Begin Mid-2027

THOMSON REUTERS
·
Jun 24

Cognition Therapeutics - to Use Neuropsychiatric Inventory as Primary Endpoint in Pivotal Dlb Psychosis Trial

THOMSON REUTERS
·
Jun 24

H.C. Wainwright Reaffirms Their Buy Rating on Cognition Therapeutics (CGTX)

TIPRANKS
·
Jun 22

Cognition Therapeutics Shareholders Elect Directors, Ratify Auditor

TIPRANKS
·
Jun 18

Cognition Therapeutics shareholders elect Aaron Fletcher, Lisa Ricciardi as Class II directors

Reuters
·
Jun 18

Cognition Therapeutics Receives Patent Allowance for Polymorphic Crystalline Form of Zervimesine

MT Newswires Live
·
Jun 16

Cognition Therapeutics says USPTO allows zervimesine patent application extending protection to 2045

Reuters
·
Jun 16

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

GlobeNewswire
·
Jun 16

Cognition Therapeutics (CGTX) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Jun 09

Cognition Therapeutics Advances Zervimesine Toward Phase 3 DLB Trial

TIPRANKS
·
Jun 04

Cognition Therapeutics CEO presents at Jefferies Global Healthcare Conference

Reuters
·
Jun 01

Cognition Therapeutics Participating in Upcoming Investor Conferences

GlobeNewswire
·
Jun 01

Peter Thiel-Backed AI Coding Startup Cognition Hits $26 Billion Valuation

Dow Jones
·
May 28

KDventures Portfolio Firm Highlights Severe Fatigue as Key Unmet Need in PBC

TIPRANKS
·
May 27

Cognition Therapeutics Advances Zervimesine Toward Late-Stage DLB Trial

TIPRANKS
·
May 21

Cognition Therapeutics plans late-stage zervimesine trial for Lewy body dementia psychosis

Reuters
·
May 21

Cognition Therapeutics Completes Meeting With FDA for Zervimesine (Ct1812) in Dementia With Lewy Bodies With Psychosis

THOMSON REUTERS
·
May 21

Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis

GlobeNewswire
·
May 21

Press Release: Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

Dow Jones
·
May 14

Analysts Offer Insights on Healthcare Companies: Rockwell Med (RMTI), 4D Molecular Therapeutics (FDMT) and Cognition Therapeutics (CGTX)

TIPRANKS
·
May 09